Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.39 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.38 |
| ▸ | KAT7 | O95251 | 2/20 | 0.37 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.37 |
| ▸ | MMP1 | P03956 | 1/20 | 0.36 |
| ▸ | MMP3 | P08254 | 1/20 | 0.36 |
| ▸ | MMP7 | P09237 | 1/20 | 0.36 |
| ▸ | MMP9 | P14780 | 1/20 | 0.36 |
| ▸ | TRPV3 | Q8NET8 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | KAT8 | Q9H7Z6 | 1/20 | 0.35 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.35 |
| ▸ | IDO1 | P14902 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28542510 | 0.89 | SMARCA2 (0.40) | GPR119NR1H2KAT7ALDH1A1KAT8 | |
| SCHEMBL21700902 | 0.87 | MC2R (0.35) | ALDH1A1 | |
| SCHEMBL28532826 | 0.85 | MAPT (0.39) | GPR119NR1H2KAT7MMP1MMP3 | |
| SCHEMBL30138120 | 0.81 | USP30 (0.44) | NR1H2USP30MMP1MMP3MMP7 | |
| SCHEMBL28910516 | 0.80 | MC2R (0.54) | — | |
| SCHEMBL31188860 | 0.80 | MC2R (0.54) | — | |
| SCHEMBL13419755 | 0.76 | NR1H2 (0.45) | GPR119NR1H2USP30 | |
| SCHEMBL21701034 | 0.75 | CFD (0.35) | ALDH1A1 | |
| SCHEMBL26131612 | 0.74 | SMARCA2 (0.49) | GPR119USP30 | |
| SCHEMBL26129909 | 0.74 | SMARCA2 (0.49) | GPR119USP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3802500-B1 | MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF | CRINETICS PHARMACEUTICALS INC (US) | 2026-05-27 | — | — | EP | disclosed |
| US-12479828-B2 | Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof | Crinetics Pharmaceuticals, Inc. (US) | 2025-11-25 | — | — | US | disclosed |
| CN-112533904-B | Melanocortin subtype-2 receptor (MC 2R) antagonists and uses thereof | 克林提克斯医药股份有限公司 | 2024-10-29 | — | — | CN | disclosed |
| US-20240300920-A1 | MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. | 2024-09-12 | — | — | US | disclosed |
| US-20240109866-A1 | MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. | 2024-04-04 | — | — | US | disclosed |
| US-11566015-B2 | Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof | Crinetics Pharmaceuticals, Inc. (US) | 2023-01-31 | — | — | US | disclosed |
| CN-112533904-A | Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof | 克林提克斯医药股份有限公司 | 2021-03-19 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11566015-B2 | Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof | MC3R, MC1R, MC2R | GPR119 60/4885NR1H2 564/4885KAT7 2834/4885 |
| US-20240109866-A1 | MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF | MC3R, MC1R, MC2R | GPR119 60/4885NR1H2 564/4885KAT7 2834/4885 |
| US-20240300920-A1 | MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF | MC3R, MC1R, MC2R | GPR119 60/4885NR1H2 564/4885KAT7 2834/4885 |
| US-12479828-B2 | Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof | MC3R, MC1R, MC2R | GPR119 60/4885NR1H2 564/4885KAT7 2834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.